All Stories

  1. Complete response associated with lenalidomide and celecoxib in a case of primary refractory Hodgkin lymphoma

    Article • OncoTargets and Therapy, October 2018, Dove Medical Press

    Dr Jordi Martinez-Serra

  2. Lenalidomide, celecoxib, and azacitidine therapy for blastic plasmocytoid dendritic cell neoplasm: a case report

    Article • OncoTargets and Therapy, September 2016, Dove Medical Press

    Dr Jordi Martinez-Serra, Marta García-Recio

  3. Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma

    Article • OncoTargets and Therapy, November 2014, Taylor & Francis

    Dr Jordi Martinez-Serra

  4. Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis

    Article • Biomarker Research, August 2014, Springer Science + Business Media

    Dr Jordi Martinez-Serra

  5. Real-time monitoring of leukemia cells

    Article • OncoTargets and Therapy, June 2014, Taylor & Francis

    Dr Jordi Martinez-Serra, Ms María Navarro-Palou

  6. Genotyping without DNA purification

    Article • Journal of Blood Medicine, June 2014, Taylor & Francis

    Dr Jordi Martinez-Serra

  7. Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: New molecular insight into the mechanism of action

    Article • European Journal of Pharmacology, May 2011, Elsevier

    Dr Jordi Martinez-Serra

  8. Rapid triplex asymmetric real-time PCR hybridization probe assay for the joint genotyping of F2, F5 and F12

    Article • Clinical Biochemistry, August 2009, Elsevier

    Dr Jordi Martinez-Serra

  9. Inhibition of c-Myc Down-Regulation by Sustained Extracellular Signal-Regulated Kinase Activation Prevents the Antimetabolite Methotrexate- and Gemcitabine-Induced Differentiation in Non-Small-Cell Lung Cancer Cells

    Article • Molecular Pharmacology, March 2008, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Jordi Martinez-Serra